Hollie Franklin, Author at Drugs in Context

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks

Andrea De Giglio, Biagio Ricciuti, Giulio Metro

Article Type

Editorial

Published

02 May 2023

This Editorial by De Giglio, Ricciuti and Metro introduces the series Treatment of advanced non-small-cell lung cancer: one size does not fit all.

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti

Article Type

Review

Published

02 May 2023

This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies.

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris

Article Type

Review

Published

13 Apr 2023

This multicentre, retrospective study evaluates the efficacy and safety of risankizumab in a population of psoriatic patients with palmoplantar involvement over a 52-week treatment period.

Multidisciplinary approach, continuous care and opioid management in cancer pain: case series and review of the literature

Giampiero Porzio, Andreia Capela, Raffaele Giusti, Francesca Lo Bianco, Mirella Moro, Giulio Ravoni, Katarzyna Zułtak-Baczkowska

Article Type

Original Research

Published

11 Apr 2023

This narrative literature review emphasizes the value of providing all patients with multidisciplinary pain management in their preferred care setting. Real-life experiences are also reported to witness the efforts of physicians to properly manage cancer pain.

Silymarin in the management of liver enzyme activity in steatohepatitis: a case report

Aldo Torre

Article Type

Case Report

Published

06 Apr 2023

This case report discusses personalized management of a patient with metabolic-associated fatty liver disease with advanced fibrosis and severe steatosis. The article examines impact of silymarin use, concomitant treatment with diet, exercise, insulin sensitizers and antifibrotic agents.